Tech Company Financing Transactions
Hemanext Funding Round
Private investors participated in a $18 million Series B funding round for Hemanext. The round was announced by the company on 11/7/2022.
Transaction Overview
Company Name
Announced On
11/7/2022
Transaction Type
Venture Equity
Amount
$18,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
99 Hayden Avenue Building B 620
Lexington, MA 02421
USA
Lexington, MA 02421
USA
Phone
Website
Email Address
Not Recorded
Overview
Hemanext is a medical technology company with corporate headquarters in Lexington, MA and manufacturing operations in Avon, MA. Our corporate mission is to support the transfusion medicine community in its efforts to save lives and improve patient outcomes. Our distinctive focus is on innovations that promote dramatic improvements in transfusion therapy.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Martin Cannon
Chief Financial Officer
Eric Newman
Chief Medical Officer
Laurel Omert
Chief Scientific Officer
Andrew Dunham
VP - Human Resources
Jill Buckley
VP - Marketing
Alex Marichal
VP - Operations
Robert Haime
VP - Product Management
Laura Daniels
Browse more venture capital transactions:
Prev: 11/7/2022: Rivalry Tech venture capital transaction
Next: 11/7/2022: Emerge Career venture capital transaction
Share this article
About Database of VC Transactions
We do our best to document funding rounds that are announced publicly. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs